Publication | Closed Access
O-108 Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC
54
Citations
0
References
2003
Year
Advanced NsclcMedicineClinical TrialsPathologyPharmacotherapyAntisense TherapyCancer TreatmentOncologyRadiation OncologyAntisense Oligonucleotide Ly900003Novel TherapyIsis 3521Health Sciences
No additional data available for this publication yet. Check back later!